Basic information Safety Related Supplier

ChemicalBook Product Catalog Biochemical Engineering Biochemical Reagents Agonist Inhibitors AZM475271

1/1

AZM475271 NEW

$29.00 2mg

$29.00 2mg

$29.00 2mg

$29.00 2mg

Purity99.78%
Cas No476159-98-5
Supply Ability10g
Update time2026-08-20

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP7Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	AZM475271
CAS No	476159-98-5
EC-No
Purity	99.78%
Supply Ability	10g
Release date	2026/08/20

Product Introduction

Bioactivity

Name	AZM475271
Description	AZM475271 is a selective Src family kinase inhibitor that potently blocks both smooth muscle contraction and stromal cell growth in human prostate tissue at 10 μM concentrations. The compound disrupts actin cytoskeletal organization and reduces proliferation through an SFK-dependent process, effectively inhibiting α1-adrenoceptor-mediated and neurogenic contraction of prostate strips. Additionally, AZM475271 suppresses TGF-β1-induced cell migration and epithelial-mesenchymal transition in pancreatic carcinoma cells by blocking Smad2 and Smad3 activation along with downstream gene expression changes. This dual mechanism of action makes the compound a valuable research tool for studying Src-dependent signaling pathways in cancer biology and benign prostatic hyperplasia models.
In vitro	AZM475271 demonstrated strong dose-dependent inhibition of Src tyrosine kinase activity in the L3.6pl human pancreatic carcinoma cell line. The IC50 concentration of AZM475271 to inhibit the phosphorylation of c-src, lck, and c-yes was 0.01, 0.03, and 0.08 μmol/L, respectively, in comparison with an IC50 of 0.7 μmol/L AZM475271 to inhibit KDR [2]. Maximum reduction of Src kinase activity was observed after incubation for 4 hours with ≥5 μmol/L.
In vivo	Treatment with gemcitabine or AZM475271 alone did not significantly change animal weight [2]. In vivo: Tumors appeared to be palpable at day 14 after tumor cell injection in all animals except mice treated with both AZM475271 and gemcitabine, in which the earliest possible palpation of the tumors was at day 17 after tumor cell injection.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 42 mg/mL (94.82 mM), Sonication is recommended.
Keywords	M-475271 \| M 475271 \| AZM-475271 \| AZM475271 \| AZM 475271
Inhibitors Related	Stavudine \| Aceglutamide \| Urea \| Tamoxifen \| Cysteamine hydrochloride \| Metronidazole \| Citric Acid Triammonium \| Formamide \| Dimethyl phthalate \| Alginic acid \| Sodium Molybdate \| Sildenafil citrate

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy